Compendium of the most significant studies with reference to properties, intake, effects.

Bernstein DI, Berkowitz RB, Chervinsky P, Dvorin DJ, Finn AF, Gross GN, Karetzky M, Kemp JP, Laforce C, Lumry W, Mendelson LM, Nelson H, Pearlman D, Rachelefsky G, Ratner P, Repsher L, Segal AT, Selner JC, Settipane GA, Wanderer A, Cuss FM, Nolop KB, Harrison JE. Dose-ranging study of a new steroid for asthma: mometasone furoate dry powder inhaler. Respir Med. 1999 Sep;93(9):603-12. doi: 10.1016/s0954-6111(99)90099-9.

Abstract A new formulation of mometasone furoate (MF) for administration by dry powder inhaler (DPI) was evaluated for the treatment of asthma. A 12-week, double-blind, placebo-controlled dose-ranging study compared the efficacy and safety of three doses of MF DPI (100, 200 and 400 mcg b.i.d) with beclomethasone dipropionate (BDP) 168 mcg b.i.d. administered by metered dose inhaler in 365 adult or adolescent patients being treated with inhaled glucocorticoids....

Prakash A, Benfield P. Topical mometasone. A review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders. Drugs. 1998 Jan;55(1):145-63. doi: 10.2165/00003495-199855010-00009.

 Abstract  ....Mometasone is a well tolerated topical glucocorticoid effective in the management of patients with atopic dermatitis, seborrhoeic dermatitis, scalp psoriasis and psoriasis vulgaris. In addition to its low potential for causing primary sensitisation and cross-reactions with other topical glucocorticoids, mometasone offers the convenience of once-daily administration.

Hoffmann K, Auer T, Stücker M, Hoffmann A, Altmeyer P. Comparison of skin atrophy and vasoconstriction due to mometasone furoate, methylprednisolone and hydrocortisone. J Eur Acad Dermatol Venereol. 1998 Mar;10(2):137-42.

Abstract Conclusion: In summary, the synthetic steroids mometasone furoate and methylprednisolone aceponate presented side-effects similar to those of hydrocortisone but much greater vasoconstrictor effect; after an application period of over 5 days under occlusion a blanching effect in our model was not demonstrable by means of chromometry. Two-dimensional laser scanning offers no advantage in the evaluation of the blanching effect in comparison to one-dimensional laser fluxmetry.

Cervin A, Rimmer J, Wrobel A, Abelak Y, Brayton L, Kuang Y. Long-acting implantable corticosteroid matrix for chronic rhinosinusitis: Results of LANTERN Phase 2 randomized controlled study. Int Forum Allergy Rhinol. 2021 Sep 17. doi: 10.1002/alr.22883.

 Abstract. Conclusions:  LYR-210 is the first implantable sinonasal treatment to achieve up to 24 weeks of benefit from a single administration in surgically naive chronic rhinosinusitis patients with and without nasal polyps.

Webster KE, O'Byrne L, MacKeith S, Philpott C, Hopkins C, Burton MJ. Interventions for the prevention of persistent post-COVID-19 olfactory dysfunction. Cochrane Database Syst Rev. 2021 Jul 22;7(7):CD013877. doi: 10.1002/14651858.CD013877.pub2.

Bartels C, Jain M, Yu J, Tillmann HC, Vaidya S. Population Pharmacokinetic Analysis of Indacaterol/Glycopyrronium/Mometasone Furoate After Administration of Combination Therapies Using the Breezhaler® Device in Patients with Asthma. Eur J Drug Metab Pharmacokinet. 2021 Jul;46(4):487-504. doi: 10.1007/s13318-021-00689-x.

Mometasone furoate (9α,21‐dichloro‐11β,17α –dihydroxy‐16α‐methyl‐pregna‐1,4‐diene‐3,20‐dione‐17‐(2′) furoate) is a chemical compound, corticosteroid, 17-ester furoate of mometasone, shows less affinity for dermal cells than epidermal cells and esterification at position 17 increases the lipophilicity of mometasone. This chemical compound has the effect of reaching a therapeutic concentration in the skin without being toxic.

It is a white to whitish powder practically insoluble in water, slightly soluble in octanol and moderately soluble in ethyl alcohol.

Its properties are:

• anti-inflammatory
• vasoconstrictive
• antipruriginous

Significant improvements over a range of subjective and objective endpoints, including a reduction in the need for sinus surgery by 61%, suggest that Mometasone furoate sinus implants may play an important role in management of recurrent nasal polyps (1).

The first-line drugs for the pharmacotherapy of allergic rhinitis are, generally, corticosteroids, and treatment with Mometasone furoate nasal spray has been shown to be effective (2).

After the fifth day after tonsillectomy surgery in children, pain generally increases because it coincides with a time of intense wound inflammation. To relieve this pain, Mometasone furoate in the form of nasal spray has demonstrated analgesic effect and thus clinical importance to overcome this problem (3).

Asthma is a chronic inflammatory disease that causes significant morbidity and mortality. Inhaled corticosteroids are the preferred initial treatment for this disorder. For patients with persistent asthma who require treatment with an inhaled corticosteroid, mometasone furoate is an excellent therapeutic choice (4).

Mometasone furoate studies

Molecular Formula: C₂₇H₃₀Cl₂O₆

Molecular Weight : 521.4 g/mol

CAS: 83919-23-7

UNII 04201GDN4R

EC Number: 

DSSTox Substance ID: DTXSID4023333

MDL number  MFCD00866003

PubChem Substance ID 329823374

NACRES: NA.24

Synonims: 

• 9α,21-dichloro-11β-hydroxy-16α-methyl 3,20-dioxopregna-1,4-dien-17-yl furan-2-carboxylate
• (11β,16α)-9,21-Dichloro-17-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-methylpregna-1,4-diene-3,20-dione
• Nasonex
• Asmanex
• Danitin
• (8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl furan-2-carboxylate

References_____________________________________________________________

(1) Kern RC, Stolovitzky JP, Silvers SL, Singh A, Lee JT, Yen DM, Iloreta AMC Jr, Langford FPJ, Karanfilov B, Matheny KE, Stambaugh JW, Gawlicka AK; RESOLVE II study investigators. A phase 3 trial of mometasone furoate sinus implants for chronic sinusitis with recurrent nasal polyps. Int Forum Allergy Rhinol. 2018 Apr;8(4):471-481. doi: 10.1002/alr.22084.

(2) Shikh EV, Eremenko NN, Arefev KI. Farmakoterapiya allergicheskogo rinita: pozitsiya klinicheskogo farmakologa [Pharmacotherapy of allergic rhinitis: position of a clinical pharmacologist. Vestn Otorinolaringol. 2021;86(3):118-126. Russian. doi: 10.17116/otorino202186031118.

(3) Unsal O, Akpinar M, Bozkurt G, Soytas P, Ekici M, Turk B, Coskun BU. Nasal Sprays Containing Mometasone Furoate for Relief of Post-Adenotonsillectomy Pain in Children: A Prospective Controlled Study. Sisli Etfal Hastan Tip Bul. 2021 Mar 17;55(1):101-107. doi: 10.14744/SEMB.2020.75735.

(4) Fausnight TB, Craig TJ. Mometasone furoate dry powder inhaler for the treatment of asthma. Expert Opin Pharmacother. 2011 Dec;12(17):2707-12. doi: 10.1517/14656566.2011.630390.